カテゴリー： Market Monitor Global, 世界, 医療/バイオ

全身性アスペルギルス症＆全身性カンジダ症の世界市場見通し2023年-2029年

◆英語タイトル：Systemic Aspergillosis and Systemic Candidasis Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8694 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：78 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Systemic Aspergillosis and Systemic Candidasis Market 調査レポートは次の情報を含め、グローバルにおけるの全身性アスペルギルス症＆全身性カンジダ症市場規模と予測を収録しています。・世界の全身性アスペルギルス症＆全身性カンジダ症市場：売上、2018年-2023年、2024年-2029年
・世界の全身性アスペルギルス症＆全身性カンジダ症市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の全身性アスペルギルス症＆全身性カンジダ症市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ボリコナゾール」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

全身性アスペルギルス症＆全身性カンジダ症のグローバル主要企業は、Novartis AG、 Pfizer, Inc、 Sanofi-Aventis、 Merck & Co., Inc、 Enzon Pharmaceuticals, Inc、 Bayer AG、 Astellas Pharma, Inc、 GlaxoSmithKline plc、 Abbottなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、全身性アスペルギルス症＆全身性カンジダ症のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の全身性アスペルギルス症＆全身性カンジダ症市場：タイプ別、2018年-2023年、2024年-2029年
世界の全身性アスペルギルス症＆全身性カンジダ症市場：タイプ別市場シェア、2022年
・ボリコナゾール、リポソームアムホテリシンB、全身性経口アゾール、局所抗真菌薬、その他

世界の全身性アスペルギルス症＆全身性カンジダ症市場：用途別、2018年-2023年、2024年-2029年
世界の全身性アスペルギルス症＆全身性カンジダ症市場：用途別市場シェア、2022年
・CPA、ABPA、消化管カンジダ症、泌尿生殖器カンジダ症、その他

世界の全身性アスペルギルス症＆全身性カンジダ症市場：地域・国別、2018年-2023年、2024年-2029年
世界の全身性アスペルギルス症＆全身性カンジダ症市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における全身性アスペルギルス症＆全身性カンジダ症のグローバル売上、2018年-2023年
・主要企業における全身性アスペルギルス症＆全身性カンジダ症のグローバル売上シェア、2022年
・主要企業における全身性アスペルギルス症＆全身性カンジダ症のグローバル販売量、2018年-2023年
・主要企業における全身性アスペルギルス症＆全身性カンジダ症のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Novartis AG、 Pfizer, Inc、 Sanofi-Aventis、 Merck & Co., Inc、 Enzon Pharmaceuticals, Inc、 Bayer AG、 Astellas Pharma, Inc、 GlaxoSmithKline plc、 Abbott

*************************************************************

・調査・分析レポートの概要
全身性アスペルギルス症＆全身性カンジダ症市場の定義
市場セグメント
世界の全身性アスペルギルス症＆全身性カンジダ症市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の全身性アスペルギルス症＆全身性カンジダ症市場規模
世界の全身性アスペルギルス症＆全身性カンジダ症市場規模：2022年 VS 2029年
世界の全身性アスペルギルス症＆全身性カンジダ症市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの全身性アスペルギルス症＆全身性カンジダ症の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の全身性アスペルギルス症＆全身性カンジダ症製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ボリコナゾール、リポソームアムホテリシンB、全身性経口アゾール、局所抗真菌薬、その他
全身性アスペルギルス症＆全身性カンジダ症のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：CPA、ABPA、消化管カンジダ症、泌尿生殖器カンジダ症、その他
全身性アスペルギルス症＆全身性カンジダ症の用途別グローバル売上・予測

・地域別市場分析
地域別全身性アスペルギルス症＆全身性カンジダ症市場規模 2022年と2029年
地域別全身性アスペルギルス症＆全身性カンジダ症売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Novartis AG、 Pfizer, Inc、 Sanofi-Aventis、 Merck & Co., Inc、 Enzon Pharmaceuticals, Inc、 Bayer AG、 Astellas Pharma, Inc、 GlaxoSmithKline plc、 Abbott
...

This report aims to provide a comprehensive presentation of the global market for Systemic Aspergillosis and Systemic Candidasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Aspergillosis and Systemic Candidasis. This report contains market size and forecasts of Systemic Aspergillosis and Systemic Candidasis in global, including the following market information:
Global Systemic Aspergillosis and Systemic Candidasis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Systemic Aspergillosis and Systemic Candidasis Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Systemic Aspergillosis and Systemic Candidasis companies in 2022 (%)
The global Systemic Aspergillosis and Systemic Candidasis market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Voriconazole Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Systemic Aspergillosis and Systemic Candidasis include Novartis AG, Pfizer, Inc, Sanofi-Aventis, Merck & Co., Inc, Enzon Pharmaceuticals, Inc, Bayer AG, Astellas Pharma, Inc, GlaxoSmithKline plc and Abbott, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Systemic Aspergillosis and Systemic Candidasis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Systemic Aspergillosis and Systemic Candidasis Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Aspergillosis and Systemic Candidasis Market Segment Percentages, by Type, 2022 (%)
Voriconazole
Liposomal Amphotericin B
Systemic Oral Azoles
Topical Antifungal Agents
Other
Global Systemic Aspergillosis and Systemic Candidasis Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Aspergillosis and Systemic Candidasis Market Segment Percentages, by Application, 2022 (%)
CPA
ABPA
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Other
Global Systemic Aspergillosis and Systemic Candidasis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Systemic Aspergillosis and Systemic Candidasis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Systemic Aspergillosis and Systemic Candidasis revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Systemic Aspergillosis and Systemic Candidasis revenues share in global market, 2022 (%)
Key companies Systemic Aspergillosis and Systemic Candidasis sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Systemic Aspergillosis and Systemic Candidasis sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Pfizer, Inc
Sanofi-Aventis
Merck & Co., Inc
Enzon Pharmaceuticals, Inc
Bayer AG
Astellas Pharma, Inc
GlaxoSmithKline plc
Abbott
Outline of Major Chapters:
Chapter 1: Introduces the definition of Systemic Aspergillosis and Systemic Candidasis, market overview.
Chapter 2: Global Systemic Aspergillosis and Systemic Candidasis market size in revenue and volume.
Chapter 3: Detailed analysis of Systemic Aspergillosis and Systemic Candidasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Systemic Aspergillosis and Systemic Candidasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Systemic Aspergillosis and Systemic Candidasis capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Systemic Aspergillosis and Systemic Candidasis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Systemic Aspergillosis and Systemic Candidasis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Systemic Aspergillosis and Systemic Candidasis Overall Market Size
2.1 Global Systemic Aspergillosis and Systemic Candidasis Market Size: 2022 VS 2029
2.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Systemic Aspergillosis and Systemic Candidasis Sales: 2018-2029
3 Company Landscape
3.1 Top Systemic Aspergillosis and Systemic Candidasis Players in Global Market
3.2 Top Global Systemic Aspergillosis and Systemic Candidasis Companies Ranked by Revenue
3.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Companies
3.4 Global Systemic Aspergillosis and Systemic Candidasis Sales by Companies
3.5 Global Systemic Aspergillosis and Systemic Candidasis Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Systemic Aspergillosis and Systemic Candidasis Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Systemic Aspergillosis and Systemic Candidasis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Systemic Aspergillosis and Systemic Candidasis Players in Global Market
3.8.1 List of Global Tier 1 Systemic Aspergillosis and Systemic Candidasis Companies
3.8.2 List of Global Tier 2 and Tier 3 Systemic Aspergillosis and Systemic Candidasis Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Systemic Aspergillosis and Systemic Candidasis Market Size Markets, 2022 & 2029
4.1.2 Voriconazole
4.1.3 Liposomal Amphotericin B
4.1.4 Systemic Oral Azoles
4.1.5 Topical Antifungal Agents
4.1.6 Other
4.2 By Type – Global Systemic Aspergillosis and Systemic Candidasis Revenue & Forecasts
4.2.1 By Type – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2023
4.2.2 By Type – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2024-2029
4.2.3 By Type – Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
4.3 By Type – Global Systemic Aspergillosis and Systemic Candidasis Sales & Forecasts
4.3.1 By Type – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2023
4.3.2 By Type – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2024-2029
4.3.3 By Type – Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
4.4 By Type – Global Systemic Aspergillosis and Systemic Candidasis Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Systemic Aspergillosis and Systemic Candidasis Market Size, 2022 & 2029
5.1.2 CPA
5.1.3 ABPA
5.1.4 Gastrointestinal Candidiasis
5.1.5 Genitourinary Tract Candidiasis
5.1.6 Other
5.2 By Application – Global Systemic Aspergillosis and Systemic Candidasis Revenue & Forecasts
5.2.1 By Application – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2023
5.2.2 By Application – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2024-2029
5.2.3 By Application – Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
5.3 By Application – Global Systemic Aspergillosis and Systemic Candidasis Sales & Forecasts
5.3.1 By Application – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2023
5.3.2 By Application – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2024-2029
5.3.3 By Application – Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
5.4 By Application – Global Systemic Aspergillosis and Systemic Candidasis Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Systemic Aspergillosis and Systemic Candidasis Market Size, 2022 & 2029
6.2 By Region – Global Systemic Aspergillosis and Systemic Candidasis Revenue & Forecasts
6.2.1 By Region – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2023
6.2.2 By Region – Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2024-2029
6.2.3 By Region – Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
6.3 By Region – Global Systemic Aspergillosis and Systemic Candidasis Sales & Forecasts
6.3.1 By Region – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2023
6.3.2 By Region – Global Systemic Aspergillosis and Systemic Candidasis Sales, 2024-2029
6.3.3 By Region – Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029
6.4.2 By Country – North America Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2029
6.4.3 US Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.4.4 Canada Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.4.5 Mexico Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029
6.5.2 By Country – Europe Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2029
6.5.3 Germany Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.4 France Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.5 U.K. Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.6 Italy Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.7 Russia Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.8 Nordic Countries Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.5.9 Benelux Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029
6.6.2 By Region – Asia Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2029
6.6.3 China Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.6.4 Japan Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.6.5 South Korea Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.6.6 Southeast Asia Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.6.7 India Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029
6.7.2 By Country – South America Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2029
6.7.3 Brazil Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.7.4 Argentina Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Sales, 2018-2029
6.8.3 Turkey Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.8.4 Israel Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.8.5 Saudi Arabia Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
6.8.6 UAE Systemic Aspergillosis and Systemic Candidasis Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novartis AG
7.1.1 Novartis AG Company Summary
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.1.4 Novartis AG Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.1.5 Novartis AG Key News & Latest Developments
7.2 Pfizer, Inc
7.2.1 Pfizer, Inc Company Summary
7.2.2 Pfizer, Inc Business Overview
7.2.3 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.2.4 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer, Inc Key News & Latest Developments
7.3 Sanofi-Aventis
7.3.1 Sanofi-Aventis Company Summary
7.3.2 Sanofi-Aventis Business Overview
7.3.3 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.3.4 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.3.5 Sanofi-Aventis Key News & Latest Developments
7.4 Merck & Co., Inc
7.4.1 Merck & Co., Inc Company Summary
7.4.2 Merck & Co., Inc Business Overview
7.4.3 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.4.4 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.4.5 Merck & Co., Inc Key News & Latest Developments
7.5 Enzon Pharmaceuticals, Inc
7.5.1 Enzon Pharmaceuticals, Inc Company Summary
7.5.2 Enzon Pharmaceuticals, Inc Business Overview
7.5.3 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.5.4 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.5.5 Enzon Pharmaceuticals, Inc Key News & Latest Developments
7.6 Bayer AG
7.6.1 Bayer AG Company Summary
7.6.2 Bayer AG Business Overview
7.6.3 Bayer AG Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.6.4 Bayer AG Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.6.5 Bayer AG Key News & Latest Developments
7.7 Astellas Pharma, Inc
7.7.1 Astellas Pharma, Inc Company Summary
7.7.2 Astellas Pharma, Inc Business Overview
7.7.3 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.7.4 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharma, Inc Key News & Latest Developments
7.8 GlaxoSmithKline plc
7.8.1 GlaxoSmithKline plc Company Summary
7.8.2 GlaxoSmithKline plc Business Overview
7.8.3 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.8.4 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.8.5 GlaxoSmithKline plc Key News & Latest Developments
7.9 Abbott
7.9.1 Abbott Company Summary
7.9.2 Abbott Business Overview
7.9.3 Abbott Systemic Aspergillosis and Systemic Candidasis Major Product Offerings
7.9.4 Abbott Systemic Aspergillosis and Systemic Candidasis Sales and Revenue in Global (2018-2023)
7.9.5 Abbott Key News & Latest Developments
8 Global Systemic Aspergillosis and Systemic Candidasis Production Capacity, Analysis
8.1 Global Systemic Aspergillosis and Systemic Candidasis Production Capacity, 2018-2029
8.2 Systemic Aspergillosis and Systemic Candidasis Production Capacity of Key Manufacturers in Global Market
8.3 Global Systemic Aspergillosis and Systemic Candidasis Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Systemic Aspergillosis and Systemic Candidasis Supply Chain Analysis
10.1 Systemic Aspergillosis and Systemic Candidasis Industry Value Chain
10.2 Systemic Aspergillosis and Systemic Candidasis Upstream Market
10.3 Systemic Aspergillosis and Systemic Candidasis Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Systemic Aspergillosis and Systemic Candidasis Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Systemic Aspergillosis and Systemic Candidasis in Global Market
Table 2. Top Systemic Aspergillosis and Systemic Candidasis Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Systemic Aspergillosis and Systemic Candidasis Revenue Share by Companies, 2018-2023
Table 5. Global Systemic Aspergillosis and Systemic Candidasis Sales by Companies, (K Units), 2018-2023
Table 6. Global Systemic Aspergillosis and Systemic Candidasis Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Systemic Aspergillosis and Systemic Candidasis Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Systemic Aspergillosis and Systemic Candidasis Product Type
Table 9. List of Global Tier 1 Systemic Aspergillosis and Systemic Candidasis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Systemic Aspergillosis and Systemic Candidasis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2018-2023
Table 15. By Type - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2024-2029
Table 16. By Application – Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2018-2023
Table 20. By Application - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2024-2029
Table 21. By Region – Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Systemic Aspergillosis and Systemic Candidasis Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2018-2023
Table 25. By Region - Global Systemic Aspergillosis and Systemic Candidasis Sales (K Units), 2024-2029
Table 26. By Country - North America Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2018-2023
Table 29. By Country - North America Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2024-2029
Table 30. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2018-2023
Table 33. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2024-2029
Table 34. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2018-2023
Table 37. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2024-2029
Table 38. By Country - South America Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2018-2023
Table 41. By Country - South America Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Sales, (K Units), 2024-2029
Table 46. Novartis AG Company Summary
Table 47. Novartis AG Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 48. Novartis AG Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Novartis AG Key News & Latest Developments
Table 50. Pfizer, Inc Company Summary
Table 51. Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 52. Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Pfizer, Inc Key News & Latest Developments
Table 54. Sanofi-Aventis Company Summary
Table 55. Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 56. Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Sanofi-Aventis Key News & Latest Developments
Table 58. Merck & Co., Inc Company Summary
Table 59. Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 60. Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Merck & Co., Inc Key News & Latest Developments
Table 62. Enzon Pharmaceuticals, Inc Company Summary
Table 63. Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 64. Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Enzon Pharmaceuticals, Inc Key News & Latest Developments
Table 66. Bayer AG Company Summary
Table 67. Bayer AG Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 68. Bayer AG Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Bayer AG Key News & Latest Developments
Table 70. Astellas Pharma, Inc Company Summary
Table 71. Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 72. Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Astellas Pharma, Inc Key News & Latest Developments
Table 74. GlaxoSmithKline plc Company Summary
Table 75. GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 76. GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. GlaxoSmithKline plc Key News & Latest Developments
Table 78. Abbott Company Summary
Table 79. Abbott Systemic Aspergillosis and Systemic Candidasis Product Offerings
Table 80. Abbott Systemic Aspergillosis and Systemic Candidasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Abbott Key News & Latest Developments
Table 82. Systemic Aspergillosis and Systemic Candidasis Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 83. Global Systemic Aspergillosis and Systemic Candidasis Capacity Market Share of Key Manufacturers, 2021-2023
Table 84. Global Systemic Aspergillosis and Systemic Candidasis Production by Region, 2018-2023 (K Units)
Table 85. Global Systemic Aspergillosis and Systemic Candidasis Production by Region, 2024-2029 (K Units)
Table 86. Systemic Aspergillosis and Systemic Candidasis Market Opportunities & Trends in Global Market
Table 87. Systemic Aspergillosis and Systemic Candidasis Market Drivers in Global Market
Table 88. Systemic Aspergillosis and Systemic Candidasis Market Restraints in Global Market
Table 89. Systemic Aspergillosis and Systemic Candidasis Raw Materials
Table 90. Systemic Aspergillosis and Systemic Candidasis Raw Materials Suppliers in Global Market
Table 91. Typical Systemic Aspergillosis and Systemic Candidasis Downstream
Table 92. Systemic Aspergillosis and Systemic Candidasis Downstream Clients in Global Market
Table 93. Systemic Aspergillosis and Systemic Candidasis Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Systemic Aspergillosis and Systemic Candidasis Segment by Type in 2022
Figure 2. Systemic Aspergillosis and Systemic Candidasis Segment by Application in 2022
Figure 3. Global Systemic Aspergillosis and Systemic Candidasis Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Systemic Aspergillosis and Systemic Candidasis Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Systemic Aspergillosis and Systemic Candidasis Revenue, 2018-2029 (US$, Mn)
Figure 7. Systemic Aspergillosis and Systemic Candidasis Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Systemic Aspergillosis and Systemic Candidasis Revenue in 2022
Figure 9. By Type - Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 11. By Type - Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 12. By Type - Global Systemic Aspergillosis and Systemic Candidasis Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 15. By Application - Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 16. By Application - Global Systemic Aspergillosis and Systemic Candidasis Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 20. By Region - Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 21. By Country - North America Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 22. By Country - North America Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 23. US Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 28. Germany Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 29. France Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 37. China Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 41. India Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 43. By Country - South America Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 44. Brazil Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Systemic Aspergillosis and Systemic Candidasis Sales Market Share, 2018-2029
Figure 48. Turkey Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Systemic Aspergillosis and Systemic Candidasis Revenue, (US$, Mn), 2018-2029
Figure 52. Global Systemic Aspergillosis and Systemic Candidasis Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Systemic Aspergillosis and Systemic Candidasis by Region, 2022 VS 2029
Figure 54. Systemic Aspergillosis and Systemic Candidasis Industry Value Chain
Figure 55. Marketing Channels

※参考情報

全身性アスペルギルス症と全身性カンジダ症は、いずれも真菌による感染症であり、特に免疫力が低下している患者において重篤な病態を引き起こすことがある疾患です。これらの疾患は、病因、診断、治療、予防においても重要な側面を持っています。以下では、それぞれの特徴について詳しく考察します。

全身性アスペルギルス症は、主にアスペルギルス属の真菌によって引き起こされます。アスペルギルスは環境中に広く存在し、土壌や腐敗物、植物の残骸などに見られます。アスペルギルス感染症は、健康な人にとっては一般的に無害ですが、特に免疫抑制状態にある患者や肺疾患を持つ患者では、全身性アスペルギルス症として重篤化することがあります。この疾患の特徴としては、急激な発症と進行があり、肺炎や全身的な感染症を引き起こします。近年、ヒト免疫不全ウイルス（HIV）感染、がん患者、臓器移植を受けた患者などの増加に伴い、アスペルギルス症の発生率が増加しています。

一方、全身性カンジダ症は、カンジダ属の真菌、特にカンジダ・アルビカンスによって引き起こされます。この真菌は体内にも常在しているが、特に免疫力が低下した状況では病原性を示し、全身的な感染が発生することがあります。カンジダ症は、主に静脈カテーテルや肺換気装置の使用など、医療行為に伴って多く発生します。全身性カンジダ症は、多臓器にわたる感染を形成し、敗血症を引き起こす危険性があるため、その早期診断と治療が困難で、しばしば重篤な結果を招きます。

これらの疾患の診断は、感染の疑いがある症例に対して迅速に行われる必要があります。アスペルギルス症の場合、胸部CT検査が有用であり、特に浸潤性肺アスペルギルス症においては、特徴的な「バタフライ」状の影が見られることがあります。カンジダ症の場合も、血液培養や組織生検検査が重要な役割を果たし、感染の有無を確定することが求められます。

治療に関しては、それぞれに特有の抗真菌薬が使用されます。アスペルギルス症に対しては、アムホテリシンBやイトラコナゾール、ボリコナゾールなどが効果的とされています。一方、カンジダ症に対しては、フルコナゾールやカスポファンギン、アムホテリシンBなどが使用されます。治療の選択には、患者の状態や感染の重症度、ならびに真菌の感受性に基づいて行われます。

患者の予後は、早期の診断と適切な治療に依存します。全身性アスペルギルス症や全身性カンジダ症の発症リスクを低減するためには、免疫力を保つこと、感染管理の徹底、適切な抗真菌薬の使用が重要です。また、手術が必要な場合は、感染が蔓延する前に適切に介入することも大切です。

最近では、診断に関する新しい技術や治療法も進展しています。有望なアプローチとして、分子生物学的手法を用いた早期診断技術の開発が進められています。また、遺伝子検査技術の導入や、免疫チェックポイント阻害薬など新薬の登場が期待されています。これにより、治療の選択肢が広がり、患者の生存率の向上が図られています。

全身性アスペルギルス症と全身性カンジダ症は、疫学的にも医療的にも重要な感染症であり、今後もその予防と治療に関する研究が進むことが望まれています。これらの疾患を理解し、適切な対応をすることで、多くの患者の命を救うことができるでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 全身性アスペルギルス症＆全身性カンジダ症の世界市場見通し2023年-2029年(Systemic Aspergillosis and Systemic Candidasis Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

全身性アスペルギルス症＆全身性カンジダ症の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp